ClinicalTrials.gg
RecruitingNCT06334757Updated Mar 28, 2024

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

A Phase 2 interventional study of Serplulimab and Bevacizumab Biosimilar HLX04 in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Henan Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled May 2023, registered Mar 2024).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 7 under way, none of them phase 3. serplulimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 10
46 · median 50
Started
2023
with 5 others
Phase 2
8 of 10
3 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Henan Cancer Hospital

Among the 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is one of 6 that started in 2023, is one of 8 in phase 2, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About serplulimab

serplulimab: first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing serplulimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients.

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written before any trial-related processes;
  2. Age ≥ 18 years and ≤70 years male or females;
  3. Has a or cytologically confirmed stage IIIB/IIIC (American Joint Committee on Cancer [AJCC] 8th edition) NSCLC that is unresectable and not fit for radical concurrent chemoradiotherapy, or / recurrent non-squamous NSCLC;
  4. Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment
  5. EGFR-TKI resistance, confirmed by 1.1
  6. The Eastern Cancer Cooperative Group () performance score of 0 or 1;

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergies to any study drug
  2. Has previously received the following therapies: , anti-PD-L1 or anti-PD-L2 drugs or any other stimulatory or inhibitory agents of T cell receptors
  3. Previous exposure to VEGF inhibitor for anti-cancer treatment
  4. Patients with untreated symptomatic . Patients with treated brain metastases will be allowed if brain imaging obtained greater than 4 weeks from trial enrollment reveals stable disease.
  5. Has received a live-virus vaccination within 28 days of planned treatment start
  6. Interstitial lung disease or pneumonitis requiring oral or IV Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Serplulimab+Bevacizumab+Pemetrexed+Carboplatin

    Using Serplulimab in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.

    Drug: Serplulimab · Drug: Bevacizumab Biosimilar HLX04 · Drug: Pemetrexed · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. ORR(Overall Response Rate)

    The proportion of subjects who have a complete response (CR) or a partial response (PR)

    Time frame: From start of treatment to 12 months

Secondary outcomes

  1. PFS(Progression Free Survival)

    Time from enrollment to first disease progression assessed by investigator or death due to any cause

    Time frame: From start of treatment to 24 months

  2. OS(Overall Survival)

    Time from enrollment to the death of the subject due to any cause

    Time frame: From start of treatment to 24 months

  3. AE(Adverse Event)

    incidece of adverse drug event

    Time frame: From start of treatment to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Aug 2024, 15 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 15 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 28, 2024
StartActual
May 8, 2023
Primary completionEst.
Aug 31, 2024
CompletionEst.
Jun 30, 2025
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06334757
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
May 8, 2023
Primary completion
Aug 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Mar 28, 2024

Study contacts

zhen he
Contact
13523530961@126.com
+86 13523530961

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion